A. SREENIVASA REDDY (ABU DHABI)
Burjeel Holdings’ Board of Directors has recommended a full-year dividend of Dh120 million for 2025, equivalent to approximately Dh0.02 per ordinary share.
The recommendation was approved during a board meeting held on Wednesday and will be submitted to shareholders for approval at the company’s annual general meeting (AGM).
The recommendation follows a year of strong financial performance for the healthcare group. According to a company statement, Burjeel Holdings recorded total revenue of Dh5.49 billion in 2025, up 9.5% year-on-year, supported by patient visits exceeding 7 million, an increase of 8.4% compared with the previous year. EBITDA rose 19.9% to Dh1.09 billion, while net profit climbed 39.5% year-on-year to Dh503 million.
“2025 was a year of strong momentum for Burjeel Holdings, driven by an integrated network complemented with differentiated centres of excellence and close alignment with national healthcare priorities,” said Dr Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings.
He added that investments in the group’s ecosystem, medical leadership and people helped drive robust growth and improved earnings quality as demand for complex care continued to rise.
During the general assembly meeting held on February 27 in Abu Dhabi, shareholders approved a key amendment to the company’s articles of association allowing the positions of Chairman of the Board and Chief Executive Officer to be combined.
In line with this change, the board appointed Dr Shamsheer Vayalil as Chief Executive Officer, in addition to his current role as Founder and Chairman.
Shareholders also approved the establishment of a $1.5 billion senior unsecured sukuk issuance programme, which will allow the group to raise funds through multi-tranche issuances to eligible investors inside and outside the UAE. The sukuk, which will have a fixed tenor and will not be convertible into company shares, will rank pari passu with the company’s other unsecured obligations.
Earlier, the board authorised management to explore a share buyback programme of up to 10% of the group’s share capital, subject to regulatory approvals, reflecting confidence in the company’s growth prospects.
In another disclosure, the board reviewed and approved the company’s consolidated audited financial statements for the year ended December 31, 2025, along with the directors’ and auditors’ reports. It also approved recommendations to shareholders regarding board remuneration and the appointment of external auditors for the financial year ending December 31, 2026.
The board further approved the appointment of Ravi Rajagopal as an independent non-executive director to fill a vacant seat on the board following the resignation of Abdulmohsen Al Ashri.
Burjeel Holdings said it will continue to focus on expanding specialised care, strengthening its network of hospitals and medical centres and scaling advanced treatment capabilities across the UAE and the wider region.